DDInter1704 DDInter1676
Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventricular arrhythmias and maintaining normal sinus rhythm in atrial fibrillation or flutter.[Label,L6373,L6376]
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Sotalol {u} (Compound) resembles {v} (Compound) Atenolol
Sotalol {u} (Compound) binds {v} (Gene) ADRB1
Sotalol {u} (Compound) is included by {v} (Pharmacologic Class) Cardiac Rhythm Alteration
Sotalol {u} (Compound) causes {v} (Side Effect) Ache
Sotalol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sucralfate
Sotalol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Kaolin
Sotalol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin degludec
Sotalol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thiethylperazine
Sotalol {u} may lead to a major life threatening interaction when taken with {v} Picosulfuric acid
Sotalol {u} may lead to a major life threatening interaction when taken with {v} Terfenadine
Sotalol (Compound) resembles Atenolol (Compound)
Sotalol (Compound) binds ADRB1 (Gene)
Sotalol (Compound) is included by Cardiac Rhythm Alteration (Pharmacologic Class)
Sotalol (Compound) causes Ache (Side Effect)
Sotalol may cause a minor interaction that can limit clinical effects when taken with Sucralfate
Sotalol may cause a minor interaction that can limit clinical effects when taken with Kaolin
Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine
Sotalol may lead to a major life threatening interaction when taken with Picosulfuric acid
Sotalol may lead to a major life threatening interaction when taken with Terfenadine